Gain Therapeutics, Inc. Common Stock
GANX US36269B1052
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Islam Khalid CB |
1.00 USD |
50,000 Bought |
49,940 USD |
09/08/2024 | 09/08/2024 |
| Mack Gene CFO |
1.01 USD |
14,400 Bought |
14,544 USD |
09/08/2024 | 09/08/2024 |
| Richman Eric I O |
1.23 USD |
5,000 Bought |
6,150 USD |
01/07/2024 | 01/07/2024 |
| Richman Eric I O |
1.21 USD |
12,000 Bought |
14,520 USD |
01/07/2024 | 01/07/2024 |
| Riley Jeffrey Scott O |
3.86 USD |
30,000 Bought |
115,770 USD |
28/03/2024 | 28/03/2024 |
| Alder Matthias CEO |
2.46 USD |
206 Sold |
507 USD |
20/12/2023 | 21/12/2023 |
| Alder Matthias CEO |
2.50 USD |
1,820 Sold |
4,550 USD |
07/12/2023 | 07/12/2023 |